| Trial ID: | L4341 |
| Source ID: | NCT04341935
|
| Associated Drug: |
Linagliptin
|
| Title: |
Effects of DPP4 Inhibition on COVID-19
|
| Acronym: |
|
| Status: |
WITHDRAWN
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Coronavirus Infection|Type 2 Diabetes
|
| Interventions: |
DRUG: Linagliptin|DRUG: Insulin regimen
|
| Outcome Measures: |
Primary: Changes in Glucose Llevels, Change in glucose control will be assessed via glucose levels obtained from blood serum samples, Baseline, up to 2 weeks | Secondary: Changes in SpO2 levels, changes in SpO2 will be measured with a Pulseimetry, an indirect, non-invasive method, Baseline, up to 2 weeks|Changes in Interleukin 6 (IL6), Changes in IL 6 will be assessed from blood serum samples, Baseline, up to 2 weeks|Changes in chest structures, Changes in Chest radiography (X-ray), Baseline, up to 2 weeks
|
| Sponsor/Collaborators: |
Sponsor: University of Miami
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
PHASE4
|
| Enrollment: |
0
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT
|
| Start Date: |
2021-06-30
|
| Completion Date: |
2021-12-30
|
| Results First Posted: |
|
| Last Update Posted: |
2021-06-10
|
| Locations: |
University of Miami, Miami, Florida, 33136, United States
|
| URL: |
https://clinicaltrials.gov/show/NCT04341935
|
